SCHEMBL6328839

SCHEMBL6328839

CC/C(Nc1ccc(N(C)CCN(C)C)cc1)=C1/C(=O)Nc2cc(OC)c(OC)cc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 5/20 0.41
EGFR P00533 1/20 0.36
MAPT P10636 3/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPK1 P28482 1/20 0.35
HSD17B10 Q99714 1/20 0.35
BRD4 O60885 4/20 0.35
BRD2 P25440 2/20 0.35
CHEK1 O14757 2/20 0.35
KDR P35968 2/20 0.35
DAPK3 O43293 1/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35
PAK4 O96013 1/20 0.35
ABL1 P00519 1/20 0.35
LCK P06239 1/20 0.35
MET P08581 1/20 0.35
PDGFRB P09619 1/20 0.35
PIM1 P11309 1/20 0.35
PDGFRA P16234 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6328851 1.00 RET (0.41) RETEGFRMAPTALDH1A1MAPK1
SCHEMBL6337728 0.94 RET (0.39) RETEGFRMAPTALDH1A1MAPK1
SCHEMBL6337716 0.94 RET (0.39) RETEGFRMAPTALDH1A1MAPK1
SCHEMBL6337688 0.89 RET (0.40) RETEGFRMAPTALDH1A1MAPK1
SCHEMBL6337691 0.89 RET (0.40) RETEGFRMAPTALDH1A1MAPK1
SCHEMBL7476118 0.89 RET (0.40) RETEGFRMAPTALDH1A1MAPK1
SCHEMBL6337047 0.88 MEN1 (0.39) RETEGFRALDH1A1BRD4BRD2
SCHEMBL6337044 0.88 MEN1 (0.39) RETEGFRALDH1A1BRD4BRD2
SCHEMBL6329638 0.87 RET (0.40) RETEGFRBRD4BRD2CHEK1
SCHEMBL6329619 0.87 RET (0.40) RETEGFRBRD4BRD2CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009898-A1 New substituted indolinones, their manufacture and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-01-13 US disclosed
US-6794395-B1 Substituted indolinones, their manufacture and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009898-A1 New substituted indolinones, their manufacture and their use as medicaments CCNE1, CDK1, CCNI RET 154/4885EGFR 65/4885MAPT 3733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.